These 10 Stocks Are Squeeze Candidates Waiting to Happen

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.

Beam Therapeutics shares are trading lower. The company announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency.

Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.

Seaport Global Initiates Coverage On Dutch Bros with Buy Rating, Announces Price Target of $50

Seaport Global analyst Eric Gonzalez initiates coverage on Dutch Bros (NYSE:BROS) with a Buy rating and announces Price Target of $50.

Why Is Dutch Bros Stock Falling on Tuesday?

Dutch Bros Inc. (NYSE: BROS) stock trades lower on Tuesday as part of a wider slump across the restaurant and beverage industry.